Filing Details
- Accession Number:
- 0000899243-16-013153
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-02-11 19:23:31
- Reporting Period:
- 2016-02-09
- Filing Date:
- 2016-02-11
- Accepted Time:
- 2016-02-11 19:23:31
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1184156 | Thomas Craig | One Idexx Drive Westbrook ME 04092 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2016-02-09 | 2,054 | $17.19 | 24,352 | No | 4 | M | Direct | |
Common Stock | Disposition | 2016-02-09 | 2,054 | $69.52 | 22,298 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-Qualified Stock Option (right-to-buy) | Disposition | 2016-02-09 | 2,054 | $0.00 | 2,054 | $17.19 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2016-02-13 | No | 4 | M | Direct |
Footnotes
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $69.2738 to $69.8301 inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
- Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,527 shares on February 14, 2010, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- Not applicable.